MX2011008748A - El status de expresion de msh3 determina la sensibilidad de celulas de cancer al tratamiento quimioterapeutico con inhibidores de parp y farmacos de platino. - Google Patents
El status de expresion de msh3 determina la sensibilidad de celulas de cancer al tratamiento quimioterapeutico con inhibidores de parp y farmacos de platino.Info
- Publication number
- MX2011008748A MX2011008748A MX2011008748A MX2011008748A MX2011008748A MX 2011008748 A MX2011008748 A MX 2011008748A MX 2011008748 A MX2011008748 A MX 2011008748A MX 2011008748 A MX2011008748 A MX 2011008748A MX 2011008748 A MX2011008748 A MX 2011008748A
- Authority
- MX
- Mexico
- Prior art keywords
- sensitivity
- msh3
- cancer cells
- pharmacos
- platinum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G01N33/57535—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cell Biology (AREA)
Abstract
Se describen métodos para el tratamiento de un paciente en riesgo de o diagnosticado con cáncer colorrectal. El método de la presente invención determina la expresión global de MSH3 en células sospechosas de ser células de cáncer colorrectal del paciente y predecir la eficacia de terapia con un agente anti-neoplásico genotóxico para tratar el paciente, en donde una disminución en la expresión global de MSH3 en las células del paciente, cuando se compara con la expresión de MSH3 en células colorectales normales indica una predisposición a sensibilidad a terapia de agente anti-neoplásico genotóxico, en donde la terapia comprende administrar una cantidad efectiva de la terapia del agente anti-neoplásico genotóxico a los pacientes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161442192P | 2011-02-12 | 2011-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008748A true MX2011008748A (es) | 2012-08-31 |
Family
ID=46621117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008748A MX2011008748A (es) | 2011-02-12 | 2011-08-18 | El status de expresion de msh3 determina la sensibilidad de celulas de cancer al tratamiento quimioterapeutico con inhibidores de parp y farmacos de platino. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120207856A1 (es) |
| JP (1) | JP2012165736A (es) |
| KR (1) | KR20120093049A (es) |
| CN (1) | CN102636648A (es) |
| AR (1) | AR081874A1 (es) |
| AU (1) | AU2011202823C1 (es) |
| BR (1) | BRPI1103285A2 (es) |
| CA (1) | CA2742342A1 (es) |
| MX (1) | MX2011008748A (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104885090A (zh) | 2012-10-09 | 2015-09-02 | 凡弗3基因组有限公司 | 肿瘤克隆性分析的系统和方法 |
| LT2920168T (lt) | 2012-11-16 | 2021-10-25 | Calithera Biosciences, Inc. | Heterociklinis gliutaminazės inhibitorius |
| WO2014164730A2 (en) * | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| EP3543353A1 (en) * | 2013-09-23 | 2019-09-25 | The University of Chicago | Methods and compositions relating to cancer therapy with dna damaging agents |
| CN107027291B (zh) * | 2014-06-13 | 2020-10-30 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂的组合疗法 |
| EP3174984B1 (en) * | 2014-07-31 | 2020-05-06 | Academia Sinica | Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity |
| SG11201700816YA (en) | 2014-08-07 | 2017-02-27 | Calithera Biosciences Inc | Crystal forms of glutaminase inhibitors |
| CN104887680A (zh) * | 2015-05-08 | 2015-09-09 | 胡继承 | 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途 |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| CN108601767A (zh) | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
| CA3004504A1 (en) | 2015-11-06 | 2017-05-11 | Ventana Medical Systems, Inc. | Tissue homogenisation for representative diagnostics |
| EP3214222B1 (de) | 2016-03-02 | 2018-05-09 | Joseph Vögele AG | Einbaubohlenbaugruppe und verfahren zum betrieb deren |
| HUE064978T2 (hu) | 2016-06-29 | 2024-04-28 | Tesaro Inc | A petefészekrák kezelésének módszerei |
| MX2019013373A (es) | 2017-05-09 | 2020-08-03 | Tesaro Inc | Terapias de combinación para tratar cáncer. |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| EP3691685A1 (en) | 2017-10-06 | 2020-08-12 | Tesaro Inc. | Combination therapies and uses thereof |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
| BR112020013214A2 (pt) * | 2017-12-27 | 2020-12-01 | Tesaro, Inc. | métodos para tratar um câncer |
| WO2021037978A1 (en) * | 2019-08-28 | 2021-03-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of cancer |
| WO2022098086A1 (ko) * | 2020-11-04 | 2022-05-12 | 한국과학기술원 | 비기능성 전사체를 이용한 parp 저해제 또는 dna 손상 약물 감수성 판정방법 |
| CN113667750B (zh) * | 2021-08-11 | 2022-05-17 | 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) | 一种用于结直肠癌诊断的circRNA标志物的应用 |
| CN118615452A (zh) * | 2023-03-07 | 2024-09-10 | 中国科学院分子细胞科学卓越创新中心 | Dna损伤药物联合化疗 |
| WO2025183523A1 (ko) * | 2024-02-29 | 2025-09-04 | 아주대학교 산학협력단 | Parp 억제제 감수성 증가 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2163650T3 (en) * | 2004-04-09 | 2015-11-02 | Genomic Health Inc | Genekspressionsmarkører for prediction of response to chemotherapy |
| CN101238373A (zh) * | 2005-08-19 | 2008-08-06 | 因迪维姆德有限公司 | 内质蛋白片段及其衍生物作为结肠直肠腺瘤和/或癌的生物标记的用途；用于检测的方法和测试系统 |
| EP2092083A2 (en) * | 2006-10-20 | 2009-08-26 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
| US7618992B2 (en) * | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| WO2009114836A1 (en) * | 2008-03-14 | 2009-09-17 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
-
2011
- 2011-06-07 CA CA2742342A patent/CA2742342A1/en not_active Abandoned
- 2011-06-10 AR ARP110102043A patent/AR081874A1/es unknown
- 2011-06-14 AU AU2011202823A patent/AU2011202823C1/en not_active Ceased
- 2011-07-19 JP JP2011157861A patent/JP2012165736A/ja active Pending
- 2011-07-28 BR BRPI1103285-5A patent/BRPI1103285A2/pt not_active Application Discontinuation
- 2011-07-29 KR KR1020110075994A patent/KR20120093049A/ko not_active Ceased
- 2011-08-10 CN CN2011102283463A patent/CN102636648A/zh active Pending
- 2011-08-18 MX MX2011008748A patent/MX2011008748A/es not_active Application Discontinuation
-
2012
- 2012-02-10 US US13/370,752 patent/US20120207856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR081874A1 (es) | 2012-10-24 |
| AU2011202823B2 (en) | 2012-12-13 |
| CA2742342A1 (en) | 2012-08-12 |
| KR20120093049A (ko) | 2012-08-22 |
| JP2012165736A (ja) | 2012-09-06 |
| CN102636648A (zh) | 2012-08-15 |
| AU2011202823A1 (en) | 2012-08-30 |
| US20120207856A1 (en) | 2012-08-16 |
| BRPI1103285A2 (pt) | 2013-11-05 |
| AU2011202823C1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008748A (es) | El status de expresion de msh3 determina la sensibilidad de celulas de cancer al tratamiento quimioterapeutico con inhibidores de parp y farmacos de platino. | |
| MX2015014486A (es) | Marcadores de respuesta de células tumorales a la terapia. | |
| MX2013011582A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinasolinas sustituidas. | |
| WO2014205555A8 (en) | Methods and uses for diagnosis and treatment of prostate cancer | |
| WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| EA201792650A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| MX342735B (es) | Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. | |
| MX352789B (es) | Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio. | |
| NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| TR201818927T4 (tr) | Kataterlerde İyileştirme | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| EP3879269A3 (en) | Methods of measuring signaling pathway activity for selection of therapeutic agents | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| MX376077B (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
| CL2023003003A1 (es) | Tratamiento y diagnóstico de trastornos inflamatorios | |
| CY1119867T1 (el) | Αναστολεις vap-1 για χρηση στη θεραπεια ινωτικων καταστασεων | |
| MX2020006660A (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato. | |
| AR085837A1 (es) | Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer | |
| ES2671248T3 (es) | Métodos para tratar el cáncer que comprenden un guiado por NQO1 | |
| WO2012138691A3 (en) | Diagnosis and treatment of taxane-resistant cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |